Detection of Human Papillomavirus in Anal Specimens Using the Hybrid Capture 2 Assay

Lowe, Brian; Goldstone, Stephen E.; Rus, Szymon; Salim, Hiam; Chen, Guorong; Rothmann, Thomas; Nazarenko, Irina

doi:10.1097/pdm.0b013e318249fd6b

Cited by 11 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, HC2 is mainly used to detect high-risk HPV infection in cervical samples. HC2 has also been used to test for high-risk HPV infection in anal and oral samples [Chaudhary et al, 2010;Jarboe et al, 2011;Goldstone et al, 2012;Lowe et al, 2012]. HC2 provides another technique for screening for high-risk HPV infection in breast samples.…”

Section: Discussionmentioning

confidence: 99%

Detection of high‐risk human papillomaviruses in fresh breast cancer samples using the hybrid capture 2 assay

Liang

Wang

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

The etiology of breast cancer remains unknown and the role of human papillomavirus (HPV) in breast carcinogenesis is controversial. This study investigated the prevalence of high-risk HPV infections in Chinese women with breast cancer and the possible relationship between high-risk HPV infection and the clinicopathological characteristics of breast cancer. Tumor cells from 224 fresh breast cancer samples and 37 fresh breast fibroadenomas were collected for hybrid capture 2 (HC2) assay. HC2 was the only technique approved by the United States Food and Drug Administration for screening for high-risk HPV infection in 2008. The prevalence of high-risk HPV infection in breast cancer samples was 21.4%, which was slightly higher than the 16.2% observed in breast fibroadenomas. Age and menopausal status were not risk factors for high-risk HPV infection among breast cancer patients. The clinical and pathological characteristics of breast cancer showed no significant correlation with high-risk HPV infection. Although the prevalence of 13 subtypes of high-risk HPV infections was similar in breast cancer and nonmalignant breast samples, the presence of high-risk HPVs in both malignant and benign breast samples implies that a possible causal role in breast cancer carcinogenesis could not be ruled out. Clarifying the possible link between high-risk HPVs and breast cancer might benefit women vaccinated against HPV and could decrease the incidence of HPV-related breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of high‐risk human papillomaviruses in fresh breast cancer samples using the hybrid capture 2 assay

Liang

Wang

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…At Enzo, the GYN protocol was used; and at Quest, the Non‐Gyn protocol was used. Residual specimen material was shipped to Qiagen for HC2 testing 18…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the hybrid capture 2 assay for detecting anal high‐grade dysplasia

Goldstone

Lowe

Rothmann

et al. 2012

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Hybrid Capture 2 (HC2) Human Papillomavirus (HPV) DNA TestV R is FDA approved and is a proven aid in detecting HPV infections of the cervix and as an aid in diagnosing, with cytology, cervical disease. A prospective feasibility study was conducted to determine if HC2 testing has utility when screening for high-grade anal dysplasia (AIN21). We enrolled 298 patients (45% HIV1) who had AIN21 screening with cytology, histology and HC2 testing for two specimens: a swab into liquid-based cytology medium and either a swab or a brush collection in specimen transport medium (STM). High-resolution anoscopy was performed on all patients with biopsy of AIN21 suspicious lesions. Cytology was benign (42%), atypical squamous cells of undetermined significance (30%), low-grade squamous intraepithelial lesion (18%), high-grade squamous intraepithelial lesion (1%), ASCUS possibly high-grade dysplasia (1.7%) and nondiagnostic (7%) and 36% had AIN21 histology. Sensitivity and specificity for predicting AIN21 histology for any abnormal cytology were 77 and 52%, whereas HC2 sensitivity and specificity were 91 and 40% (p 5 0.005 for sensitivity), respectively. There was no significant difference in HC2 sensitivity or specificity between brush and swab or STM and residual cells from cytology. AIN21 was found in 20% of patients with benign cytology. Only nine AIN21 specimens were HC22. This prospective study indicates that HC2 may be useful when screening for anal dysplasia; however, a larger study is recommended.

show abstract

“…Although GA has been shown to have high agreement with several other HPV genotyping assays, including LA (27), the Amplicor HPV test (48), and PCR-RFLP (43), to the best of our knowledge, GA has not yet been evaluated for HPV genotyping in anal swab samples. Screening of anal and cervical swab specimens may be different, as anal swabs may contain smaller starting amounts of DNA than cervical swabs due to their different anatomical structures and the different brushes used for sample collection, as well as possible interference in the assay by stool present in the anal samples (49).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Hybribio GenoArray and Roche Human Papillomavirus (HPV) Linear Array for HPV Genotyping in Anal Swab Samples

et al. 2015

View full text Add to dashboard Cite

g Human papillomavirus (HPV) is causally associated with anal cancer, as HPV DNA is detected in up to 90% of anal intraepithelial neoplasias and anal cancers. With the gradual increase of anal cancer rates, there is a growing need to establish reliable and clinically relevant methods to detect anal cancer precursors. In resource-limited settings, HPV DNA detection is a potentially relevant tool for anal cancer screening. Here, we evaluated the performance of the Hybribio GenoArray (GA) for genotyping HPV in anal samples, against the reference standard Roche Linear Array (LA). Anal swab samples were obtained from sexually active men who have sex with men. Following DNA extraction, each sample was genotyped using GA and LA. The overall interassay agreement, type-specific, and single and multiple genotype agreements were evaluated by kappa statistics and McNemar's 2 tests. Using GA and LA, 68% and 76% of samples were HPV DNA positive, respectively. There was substantial interassay agreements for the detection of all HPV genotypes ( ‫؍‬ 0.70, 86% agreement). Although LA was able to detect more genotypes per sample, the interassay agreement was acceptable ( ‫؍‬ 0.53, 63% agreement). GA had poorer specific detection of HPV genotypes 35, 42, and 51 ( < 0.60). In conclusion, GA and LA showed good interassay agreement for the detection of most HPV genotypes in anal samples. However, the detection of HPV DNA in up to 76% of anal samples warrants further evaluation of its clinical significance.A nal cancers are relatively rare malignancies, accounting for approximately 4% of lower gastrointestinal tract malignancies (1). Human papillomavirus (HPV) infection is causally associated with anal cancer, with HPV DNA being detected in up to 90% of anal intraepithelial neoplasias and anal cancers in both men and women (2,3). Similar to what is seen with cervical cancers, the high-risk (HR) HPV 16 is the most prevalent HPV genotype found in anal intraepithelial neoplasia and anal cancer samples (4-8). With the gradual increase of anal cancer rates (9-12), there is now a growing need for more routine anal cancer screenings and to establish reliable, reproducible, and clinically relevant methods to detect precursors to anal cancer, especially in high-risk populations like human immunodeficiency virus (HIV)-positive individuals (13). In resource-limited settings, due to the limited availability of anal cytology and high-resolution anoscopy, the detection of HPV DNA is a potentially relevant tool for anal cancer screening (14). Validated methods of HPV DNA detection and genotyping are also important for natural history studies designed to better understand the clinical relevance of these infections in the cervix and in the anal canal (15)(16)(17)(18).In this study, we evaluated the performance of Hybribio Rapid HPV GenoArray test kit (GA) (Hybribio Limited, Hong Kong) in genotyping HPV DNA extracted from anal swab samples against that of the well-established Linear Array (LA) HPV genotyping kit (Roche, USA), a widely accepted reference...

show abstract

Detection of Human Papillomavirus in Anal Specimens Using the Hybrid Capture 2 Assay

Cited by 11 publications

References 15 publications

Detection of high‐risk human papillomaviruses in fresh breast cancer samples using the hybrid capture 2 assay

Detection of high‐risk human papillomaviruses in fresh breast cancer samples using the hybrid capture 2 assay

Evaluation of the hybrid capture 2 assay for detecting anal high‐grade dysplasia

Comparison of Hybribio GenoArray and Roche Human Papillomavirus (HPV) Linear Array for HPV Genotyping in Anal Swab Samples

Contact Info

Product

Resources

About